Rare disease therapies could generate over $400 billion in global sales by 2032, a new report reveals. Evaluate’s ‘2026 Orphan Drug Report’ predicts the sales of orphan drugs will continue to rise steadily, despite policy changes and pricing turmoil. According to the forecast, orphan drugs will account for over 21% of all prescription pharmaceutical drugs by […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!